Predicting Alzheimer disease with β-amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing

Annals of Neurology

Volumn 74, Issue 6, 2013, Pages 905-913

  Rowe, Christopher C ^a   Bourgeat, Pierrick ^b   Ellis, Kathryn A ^c   Brown, Belinda ^d   Lim, Yen Ying ^c   Mulligan, Rachel ^a   Jones, Gareth ^a   Maruff, Paul ^c   Woodward, Michael ^a   Price, Roger ^e   Robins, Peter ^e   Tochon Danguy, Henri ^a   O'Keefe, Graeme ^a   Pike, Kerryn E ^a,f   Yates, Paul ^a   Szoeke, Cassandra ^g   Salvado, Olivier ^b   Macaulay, S Lance ^b   O'Meara, Timothy ^b   Head, Richard ^b   Cobiac, Lynne ^b   Savage, Greg ^h   Martins, Ralph ^d   Masters, Colin L ^c   Ames, David ^c,g   Villemagne, Victor L ^a   more..

^a AUSTIN HEALTH   (Australia)

^b CSIRO   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d EDITH COWAN UNIVERSITY   (Australia)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^f LA TROBE UNIVERSITY   (Australia)

^g NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^h MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; PITTSBURGH COMPOUND B;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; EDUCATIONAL STATUS; FEMALE; GENOTYPE; HIPPOCAMPUS; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEMORY; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; ATROPHY; AUSTRALIA; BIOLOGICAL MARKERS; FEMALE; HIPPOCAMPUS; HUMANS; LIFE STYLE; MALE; MEMORY DISORDERS; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PREDICTIVE VALUE OF TESTS; SINGLE-BLIND METHOD;

EID: 84892913370     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24040     Document Type: Article

References (38)

1. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
2. Saito Y, Murayama S,. Neuropathology of mild cognitive impairment. Neuropathology 2007; 27: 578-584.
3. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA,. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009; 66: 200-208.
4. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 12: 357-367.
5. Jack CR Jr, Wiste HJ, Lesnick TG, et al. Brain beta-amyloid load approaches a plateau. Neurology 2013; 80: 890-896.
6. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9: 1118-1127.
7. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746.
8. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-279.
9. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269.
10. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292.
11. Ellis KA, Bush AI, Darby D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009; 21: 672-687.
12. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275-1283.
13. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
14. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240-246.
15. Good CD, Johnsrude IS, Ashburner J, et al. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001; 14: 21-36.
16. Van Leemput K, Maes F, Vandermeulen D, Suetens P,. Automated model-based bias field correction of MR images of the brain. IEEE Trans Med Imaging 1999; 18: 885-896.
17. Collins DL, Zijdenbos AP, Kollokian V, et al. Design and construction of a realistic digital brain phantom. IEEE Trans Med Imaging 1998; 17: 463-468.
18. Bourgeat P, Chetelat G, Villemagne VL, et al. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010; 74: 121-127.
19. Greiner M, Sohr D, Gobel P,. A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests. J Immunol Methods 1995; 185: 123-132.
20. Knopman DS, Jack CR Jr, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012; 78: 1576-1582.
21. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009; 66: 1469-1475.
22. Perry RJ, Hodges JR,. Relationship between functional and neuropsychological performance in early Alzheimer disease. Alzheimer Dis Assoc Disord 2000; 14: 1-10.
23. Lim YY, Ellis KA, Harrington K, et al. Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-β: prodromal Alzheimer's disease? J Alzheimers Dis 2013; 33: 1167-1176.
24. Sarazin M, Berr C, De Rotrou J, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology 2007; 69: 1859-1867.
25. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010; 75: 230-238.
26. Petersen RC,. Mild cognitive impairment. Lancet 2006; 367: 1979.
27. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65: 557-568.
28. Nordberg A, Carter SF, Rinne J, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2013; 40: 104-114.
29. Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011; 76: 1085-1090.
30. Lorenzi M, Donohue M, Paternico D, et al. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiol Aging 2010; 31: 1443-1451, 1451.e1.
31. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: Diagnosis of dementia (an evidence based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143-1153.
32. Delis DC, Kramer JH, Kaplan E, Ober BA,. CVLT-II: California Verbal Learning Test. 2nd ed, adult version. San Antonio, TX: Psychological Corporation, 2000.
33. van Rossum IA, Vos S, Handels R, Visser PJ,. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 2010; 20: 881-891.
34. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force (AIT), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimer Association (AA). J Nucl Med 2013; 54: 476-490.
35. Mormino EC, Brandel MG, Madison CM, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage 2012; 59: 1152-1160.
36. Klunk WE,. Classification of amyloid-positivity in controls: comparison of objective approaches to visual reads. Paper presented at: Human Amyloid Imaging Conference; April 11, 2008; Chicago, IL.
37. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-1517.
38. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725.